ChiCTR2000028961: Combination of high-throughput sequencing and primary cell culture as an exploratory study of individualized treatment of malignant tumors: phase 2 clinical trial of sintilimab for retroperitoneal dedifferentiation of liposarcoma |
|
|
| Not yet recruiting | N/A | 30 | | Neoadjuvant sintilimab monotherapy ;Neoadjuvant sintilimab combined with epirubicin and/or ifosfamide | Department of Urology, Shanghai Changhai Hospital, the Second Military Medical University, Shanghai, China; Second Military Medical University, Innovent Biologics, Inc. | retroperitoneal dedifferentiated liposarcoma | | | | |
